<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00480272</url>
  </required_header>
  <id_info>
    <org_study_id>CURE</org_study_id>
    <secondary_id>2006-003843-22</secondary_id>
    <nct_id>NCT00480272</nct_id>
  </id_info>
  <brief_title>Prospective Study on Intensive Early Rheumatoid Arthritis Treatment</brief_title>
  <acronym>CURE</acronym>
  <official_title>A Phase IV Multicenter, Randomized, Double-blind Study. prospeCtive Study on Intensive Early Rheumatoid Arthritis Treatment With adalimUmab: Induction of REmission and Maintenance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Policlinico S. Matteo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Policlinico S. Matteo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: Early intensive treatment with anti-TNF agent plus methotrexate plus high dose&#xD;
      prednisone may increase remission rate and may induce stable remission in Rheumatoid&#xD;
      Arthritis Objective: to evaluate induction of remission using adalimumab, prednisone and&#xD;
      methotrexate and maintenance of remission after discontinuation of adalimumab and prednisone&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment group A 0 - 6 months: Adalimumab 40 mg eow + methotrexate rapidly titrated to 20 mg&#xD;
      weekly + prednisone 50 mg/d tapered to 6.25 mg 6 - 12 months: Adalimumab 40 mg eow plus&#xD;
      methotrexate 20 mg weekly group B 0 - 6 months: Adalimumab 40 mg eow + methotrexate rapidly&#xD;
      titrated to 20 mg weekly + placebo 6 - 12 months: Adalimumab 40 mg eow + methotrexate rapidly&#xD;
      titrated to 20 mg weekly&#xD;
&#xD;
      Follow up period - Open Label phase:&#xD;
&#xD;
      Patients achieving clinical remission will be than treated only with MTX and observed for&#xD;
      another 12 months period. Patients who do not achieve clinical remission or patients who will&#xD;
      experience a relapse of the disease will be treated according to standard of care (SOC)&#xD;
      modalities.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">March 1, 2017</completion_date>
  <primary_completion_date type="Actual">March 1, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>to evaluate the proportion of subjects who achieve remission at week 52 after treatment, as defined by DAS 28 &lt;/= 2.6</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>subjects who maintain stable remission at 24 months; ACR 20,50,70 at month 4,8,12,24; DAS 28 at month 4,8,12,24; HAQ at week 0,4,8,12,24; radiographic progression at months 12, 24; safety of different treatment regimens</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">251</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>adalimumab 40 mg subcutaneous injections every other week from baseline to month 12&#xD;
methotrexate orally weekly at initial dose of 10 mg rising to 20 mg weekly over 4 weeks in 2.5 mg increments, continued up to month 24.&#xD;
prednisone orally 50 mg daily, gradually tapered up to 6.25 mg at week 7 and stopped at month 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>adalimumab 40 mg subcutaneous injections every other week from baseline to the end of month 12&#xD;
methotrexate orally oweekly at an initial dose of 10 mg rising to 20 mg weekly over 4 weeks in 2.5 mg increments, continued up to month 24.&#xD;
placebo orally, stopped at month 6</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adalimumab, plus prednisone</intervention_name>
    <description>adalimumab 40 mg/sc every 2 weeks plus methotrexate 20 mg/po every week plus placebo or prednisone 50 mg/po day then reduced to 6.25/po day</description>
    <arm_group_label>group A</arm_group_label>
    <other_name>humira (adalimumab)</other_name>
    <other_name>deltacortene (prednisone)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adalimumab plus placebo</intervention_name>
    <description>adalimumab 40 mg/sc every 2 weeks plus methotrexate 20 mg/po every week plus placebo daily for 6 months</description>
    <arm_group_label>group B</arm_group_label>
    <other_name>humira (adalimumab)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Active rheumatoid arthritis diagnosed for at least 6 weeks, but no more than 1 year,&#xD;
             according to the revised 1987 ACR criteria&#xD;
&#xD;
          -  Naïve to treatment with MTX&#xD;
&#xD;
          -  Swollen joint count (SJC) &gt; 8 tender joint count (TJC) &gt; 8&#xD;
&#xD;
          -  At screening CRP &gt; 1.5 mg/dL (15 mg/L) or ESR ≥ 28 mm/h&#xD;
&#xD;
          -  ≥ 1 joint erosion or RF positivity or anti-CCP positivity&#xD;
&#xD;
          -  Age 18-70 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Rheumatic autoimmune disease other than RA&#xD;
&#xD;
          -  Functional class IV&#xD;
&#xD;
          -  Any surgical procedure within 12 weeks prior to baseline or planned during the study.&#xD;
&#xD;
          -  Pregnancy or breast feeding.&#xD;
&#xD;
          -  Evidence of significant concomitant disease&#xD;
&#xD;
          -  Primary or secondary immunodeficiency&#xD;
&#xD;
          -  active infection of any kind&#xD;
&#xD;
          -  History of previously untreated infection with mycobacterium tuberculosis or current&#xD;
             treatment for same.&#xD;
&#xD;
          -  History of cancer&#xD;
&#xD;
          -  Any history or presence of congestive heart failure (CHF) (New York Heart Association&#xD;
             classification for CHF: Class III or IV).&#xD;
&#xD;
          -  Any history of myocardial infarction within 5 years.&#xD;
&#xD;
          -  History of a severe allergic or anaphylactic reaction to a biologic agent or known&#xD;
             hypersensitivity to any component of adalimumab or methotrexate.&#xD;
&#xD;
          -  Positive serology for hepatitis B or C indicating active infection.&#xD;
&#xD;
          -  Hemoglobin &lt; 8.0 g/dL.&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &lt; 1.5 x 103/L.&#xD;
&#xD;
          -  Liver function abnormality&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>carlomaurizio montecucco, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS S. Matteo Foundation, Pavia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IRCCS S. Matteo Hospital</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>May 29, 2007</study_first_submitted>
  <study_first_submitted_qc>May 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2007</study_first_posted>
  <last_update_submitted>March 3, 2017</last_update_submitted>
  <last_update_submitted_qc>March 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Policlinico S. Matteo</investigator_affiliation>
    <investigator_full_name>Carlomaurizio Montecucco</investigator_full_name>
    <investigator_title>Director, Academic Division of Rheumatology, IRCCS Policlinico S. Matteo and University of Pavia</investigator_title>
  </responsible_party>
  <keyword>rheumatoid arthritis</keyword>
  <keyword>clinical remission</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

